AnalystsJoseph Schwartz
Joseph Schwartz's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Top 25%
#1269 out of 5184 analysts
Average Return
+3.08%
Win Rate
38%53 out of 138
Risk vs Reward
Poor
Good

Joseph Schwartz's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Maze Therapeutics IncMAZE
+310.22%$10.57$43.36
2025-02-24 -
2026-01-28
Buy
Proqr Therapeutics NvPRQR
+259.62%$5.20$18.70
2017-09-25 -
2018-09-26
Buy
Arena Pharmaceuticals IncARNA
+242.33%$13.30$45.53
2017-05-18 -
2018-05-18
Buy
Inflarx NvIFRX
+235.62%$1.46$4.90
2022-05-11 -
2023-05-11
Buy
Enliven Therapeutics IncELVN
+232.66%$6.40$21.29
2022-03-15 -
2023-03-15
Buy

Joseph Schwartz Analyst Color

Get additional color on Joseph Schwartz's coverage of popular stocks

Joseph Schwartz's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Ultragenyx Pharmaceutical IncRARE
6Buy$70.00+186.42%Maintains
a month ago
Amicus Therapeutics IncFOLD
8Hold$14.50+1.54%Downgrades
a month ago
Applied Therapeutics IncAPLT
3Hold$1.00+975.27%Downgrades
2 months ago
Spruce Biosciences IncSPRB
7Buy$160.00+95.36%Upgrades
2 months ago
Design Therapeutics IncDSGN
5Buy$14.00+38.20%Upgrades
2 months ago
Inflarx NvIFRX
4Hold$2.00+119.54%Downgrades
2 months ago
Biomarin Pharmaceutical IncBMRN
9Hold$60.00+5.86%Downgrades
2 months ago
Aurinia Pharmaceuticals IncAUPH
6Hold$16.00+9.81%Downgrades
2 months ago
Uniqure NvQURE
3Buy$60.00+160.64%Maintains
3 months ago
Monopar TherapeuticsMNPR
1Buy$115.00+70.53%Initiates Coverage On
3 months ago
Avidity Biosciences IncRNA
3Hold$72.00-0.63%Downgrades
3 months ago
Crinetics Pharmaceuticals IncCRNX
2Buy$88.00+71.47%Maintains
4 months ago
Sarepta Therapeutics IncSRPT
8Hold$15.00-29.61%Maintains
5 months ago
Kalvista Pharmaceuticals IncKALV
6Buy$20.00+32.10%Maintains
7 months ago
Insmed IncINSM
4Buy$115.00-26.23%Maintains
8 months ago
Fulcrum Therapeutics IncFULC
3Buy$12.00+14.50%Upgrades
8 months ago
Regulus Therapeutics IncRGLS
3Hold$7.00-14.22%Downgrades
9 months ago
Maze Therapeutics IncMAZE
1Buy$28.00-35.42%Initiates Coverage On
a year ago
Travere Therapeutics IncTVTX
6Buy$40.00N/AMaintains
a year ago
Solid Biosciences IncSLDB
5Buy$12.00N/AUpgrades
2 years ago
Mereo Biopharma Group PLCMREO
2Buy$8.00N/AMaintains
2 years ago
An2 Therapeutics IncANTX
2Hold$7.00N/ADowngrades
2 years ago
Synlogic IncSYBX
4Hold$1.00N/ADowngrades
2 years ago
Onkure Therapeutics IncOKUR
3Hold$10.00N/ADowngrades
2 years ago
Cartesian Therapeutics IncRNAC
2Hold$1.00N/ADowngrades
2 years ago
Chinook Therapeutics IncKDNY
3Hold$40.00N/ADowngrades
3 years ago
Reata Pharmaceuticals IncRETA
3Buy$115.00N/AUpgrades
3 years ago
Ptc Therapeutics IncPTCT
1Hold$48.00N/AInitiates Coverage On
3 years ago
Pharvaris NvPHVS
5Buy$18.00N/AMaintains
3 years ago
Ionis Pharmaceuticals IncIONS
1Hold$34.00N/AMaintains
3 years ago
Ascendis Pharma AASND
13Buy$163.00N/AMaintains
3 years ago
Applied Molecular Transport IncAMTI
6Hold$2.00N/ADowngrades
3 years ago
Gossamer Bio IncGOSS
5Buy$10.00N/AMaintains
3 years ago
Pepgen IncPEPG
2Buy$33.00N/AMaintains
3 years ago
Chemocentryx IncCCXI1
3Hold$52.00N/ADowngrades
3 years ago
Edgewise Therapeutics IncEWTX
2Buy$30.00N/AMaintains
4 years ago
Protagonist Therapeutics IncPTGX
5Buy$30.00N/AMaintains
4 years ago
Enliven Therapeutics IncELVN
4Buy$31.00N/AMaintains
4 years ago
Arena Pharmaceuticals IncARNA
6Hold$100.00N/ADowngrades
4 years ago
Spark Therapeutics IncONCE
2HoldN/AN/ADowngrades
8 years ago
Nightstar Therapeutics PLCNITE1
1Buy$25.00N/AInitiates Coverage On
8 years ago
Proqr Therapeutics NvPRQR
1Buy$12.00N/AMaintains
8 years ago
Clementia Pharmaceuticals IncCMTA
1Buy$23.00N/AInitiates Coverage On
8 years ago
Achillion Pharmaceuticals IncACHN
1BuyN/AN/AUpgrades
9 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.